Angie You, PhD

Dr. You recently served as Chief Executive Officer of Amunix Pharmaceuticals, where she orchestrated a sale of the company to Sanofi for over $1.2 billion. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology from 2014 to 2018, where she helped the company through a successful initial public offering and led the company’s strategic and transactional business and commercial efforts. Prior to Sierra Oncology, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals from 2010 through its acquisition by Johnson & Johnson in 2013. In previous roles, Dr. You served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures. Dr. You also serves on the board of ORIC Pharmaceuticals. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College.

Mary Tagliaferri, MD

Dr. Mary Tagliaferri has a highly accomplished biotechnology career and is currently Executive Clinical Fellow and Senior Vice President of Nektar Therapeutics, where she also previously served as Chief Medical Officer. Nektar is a leading research-based biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need including treatments for cancer and auto-immune disease. At Nektar, Dr. Tagliaferri has been responsible for numerous clinical studies evaluating novel therapeutics in oncology and she was also instrumental in establishing key strategic partnerships. Previously, she served as Chief Medical Officer and Chief Regulatory Officer for Kanglaite-USA and was Co-Founder, President and Board Member of Bionovo, Inc. Dr. Tagliaferri currently serves on the board of Enzo Biochem. She earned her Bachelor of Science degree at Cornell University and her medical degree at the University of California, San Francisco. Dr. Tagliaferri was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019 and was recognized as Woman of the Year, 2012, by the State of California, Assembly District 14. She has been lead author or contributor to approximately 80 peer-reviewed journal publications.

Ken Song, MD

Ken is President and CEO at RayzeBio. Ken’s experience spans clinical medicine, basic science research, product development and global commercialization, venture capital, and entrepreneurship. Ken is also the co-founder and Chairman of the Board at Ablaze Pharmaceuticals, which is focused on radiopharmaceuticals development for the Greater China market. Prior to RayzeBio, he was President and CEO of Metacrine, Inc. where he led the organization from research to mid-stage clinical development and also positioned the company for an IPO. From 2010 to 2016, Ken was the co-founder and CEO of Ariosa Diagnostics (acquired by Roche) where he led the organization from early research to global commercialization of the Harmony Prenatal Test in over 100 countries. Ken also served as Executive Chairman of Omniome (acquired by Pacific Biosciences), a sequencing technology company, helping it mature from a research to product development company.

Prior to being an operator and entrepreneur, Ken worked as a venture capitalist at Venrock as well as consultant at McKinsey & Company. Ken trained in internal medicine at the University of California, San Francisco (UCSF) and specialized in gastroenterology and hepatology at the University of Washington along with a scientific research fellowship at the Fred Hutchinson Cancer Center. He earned his B.S. from Massachusetts Institute of Technology and M.D. from UCSF.

Christy Oliger

Christy Oliger brings nearly 30 years of experience in the biopharmaceutical industry, serving in various commercial roles at Genentech, Inc. and Roche Holding AG from January 2000 until her retirement in July 2020, and at Schering-Plough Corporation from September 1992 until December 1999. Most recently, Ms. Oliger served as Senior Vice President, Oncology Business Unit Head, at Genentech, Inc. During her tenure at Genentech, Inc., Ms. Oliger held senior leadership roles across a variety of therapeutic areas, including oncology, neurology, rare diseases, respiratory, dermatology and immunology in hospital and specialty settings. She currently serves as a member of the board of directors of Reata Pharmaceuticals, Inc., and Replimune Group Inc., Karyopharm Therapeutics Inc., Lava Therapeutics, each of which is a publicly traded pharmaceutical company. Previously, Ms. Oliger also served on the board of Sierra Oncology, Inc. which was acquired by GSK for $1.9 billion. Ms. Oliger received a B.A. in Economics from the University of California at Santa Barbara. Our Board believes that Ms. Oliger is qualified to serve on our Board due to her extensive experience in commercial and portfolio management roles at biopharmaceutical companies.

Yi Larson

Yi Larson currently serves as the Chief Financial Officer of LianBio, a global biopharmaceutical company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets.

Previously, she was Executive Vice President and Chief Financial Officer of Turning Point Therapeutics, Inc., a clinical stage precision oncology company. In this role, she oversaw all aspects of the finance and accounting organization, led corporate strategy and business development, helped raise over $1 billion through 3 follow-on offerings, and spearheaded deal-making activities, including the out-licensing of Turning Point’s lead drug candidates for the Chinese market. During her tenure, Yi helped grow Turning Point from $1 billion to $5 billion+ in market cap.

Prior to Turning Point Therapeutics, Ms. Larson was a Managing Director of Healthcare Investment Banking at Goldman Sachs where she worked for over 12 years. She advised senior management teams and boards on a range of strategic and financial matters, successfully executing over 50 deals, including $70 billion in M&A activities and $30 billion in financings.

She has also served as a member of the board of directors of Olema Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, since April 2021. Ms. Larson earned an MBA, concentrated in Finance, from The Wharton School at the University of Pennsylvania. She also earned a master’s degree in Electrical Engineering and Computer Science and a bachelor’s degree in Electrical Engineering, both from the Massachusetts Institute of Technology (MIT).

Maha Katabi, PhD

Maha Katabi is a General Partner at Sofinnova Investments. Dr. Katabi is an experienced investor with over two decades in managing public and private biotech companies through bull and bear markets. She is focused on investing in development stage biopharmaceuticals and is currently a member of the board of directors of Aerovate (AVTE), Quanta, and Vera (VERA), and was recently a board member of Gyroscope (acquired by Novartis) and Amplyx (acquired by Pfizer).

Prior to joining Sofinnova in 2019, Maha was Managing Partner of Oxalis Capital.  Prior to founding Oxalis, Maha was Partner at Sectoral Asset Management, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Two of these companies were Ascendis (ASND) and Apellis (APLS), both also Sofinnova portfolio companies. Additionally, she was a Portfolio Manager for a family of funds that invested in small cap healthcare companies. She started her career in venture as a principal investor with associate and principal roles at T2C2/Bio and Ventures West.

Maha received her BSc In Biology and PhD in Pharmacology from McGill University, where she was a Cancer Research Society fellow, and is a CFA charter holder since 2011. She currently serves as Chair of the board of Exactis Innovation, a not-for profit oncology precision medicine network.

Tim Van Hauwermeiren

Tim Van Hauwermeiren, M.Sc. EMBA, has been the Chief Executive Officer and an Executive Director at argenx SE since July 2008 and July 2014 respectively. Tim co-founded argenx in 2008 having previously served as the Senior Business Development Manager of Ablynx NV. Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Prior to joining Ablynx, he held various management positions with Procter & Gamble in R&D and Corporate New Business Development. Tim currently serves on the board of iTeos Therapeutics. Tim holds Bachelor and Master of Science degree in Bio-Engineering from the University of Ghent and received general management training at INSEAD. He also holds Executive MBA from the Vlerick School of Management.

Richard Heyman, PhD (Chairman)

Dr. Heyman is an accomplished biotechnology veteran with over 25 years of operational experience. Dr. Heyman was recently the Chairman of Amunix Pharmaceuticals, Inc., which was acquired by Sanofi, and Vividion Therapeutics, which was acquired by Bayer.

Dr. Heyman currently serves on the board of directors for Enliven, ORIC Pharmaceuticals, PMV Pharma, and Vividion Therapeutics. He is also the Vice Chairman of The Salk Institute, on the Board Foundation for the American Association for Cancer Research, and on the executive committee at the University of California San Diego Moores Cancer Center. Previously, Dr. Heyman was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, two San Diego biotech companies focused on discovering and developing therapeutics targeting hormone-dependent cancers. Johnson & Johnson purchased Aragon in 2013 and Genentech/Roche purchased Seragon in 2014. He was an NIH postdoctoral fellow at the Salk Institute, and received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.